SCHEMBL1983011

SCHEMBL1983011

COc1ccc(S(=O)(=O)c2cc3cnc([S+](C)[O-])nc3n(C)c2=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK2 Q9NYY3 6/20 0.56
RIPK2 O43353 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
FGFR1 P11362 2/20 0.39
FGFR2 P21802 1/20 0.39
FGFR4 P22455 1/20 0.39
FGFR3 P22607 1/20 0.39
EGFR P00533 1/20 0.39
SRC P12931 1/20 0.39
PKM P14618 2/20 0.38
POLB P06746 1/20 0.37
HTT P42858 1/20 0.37
CNR2 P34972 1/20 0.37
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CASP1 P29466 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13385778 0.88 PLK2 (0.44) PLK2RIPK2RXFP1FGFR1EGFR
SCHEMBL13385833 0.87 PLK2 (0.44) PLK2RIPK2RXFP1FGFR1EGFR
SCHEMBL13385787 0.87 PLK2 (0.55) PLK2RIPK2FGFR1EGFRSRC
SCHEMBL1981813 0.87 PLK2 (0.44) PLK2RIPK2FGFR1FGFR2FGFR4
SCHEMBL1980199 0.87 PLK2 (0.55) PLK2RIPK2FGFR1FGFR2FGFR4
SCHEMBL13385788 0.82 PLK2 (0.57) PLK2RIPK2RXFP1FGFR1FGFR2
SCHEMBL1980519 0.81 PLK2 (0.43) PLK2RIPK2FGFR1EGFRSRC
SCHEMBL1981941 0.79 PLK2 (0.56) PLK2NEK2NEK5NEK1
SCHEMBL13385913 0.77 PLK2 (0.73) PLK2RIPK2FGFR1FGFR4EGFR
SCHEMBL13385817 0.76 PLK2 (0.72) PLK2RIPK2FGFR1EGFRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889696-B2 Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof Temple University—Of the Commonwealth System of Higher Education (US) 2014-11-18 US disclosed
US-20120269831-A1 SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-10-25 US disclosed
EP-2512250-A1 SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF Temple University - Of The Commonwealth System of Higher Education (US) 2012-10-24 EP disclosed
WO-2011075616-A1 SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120269831-A1 SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF MKI67, CCNA1, FOLR1 PLK2 224/4885RIPK2 4392/4885RXFP1 590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.